Connect with us

Uncategorized

Cubic burning through cash as insolvency risk looms ahead: Glasshouse Research

Cubic burning through cash as insolvency risk looms ahead: Glasshouse Research

Published

on

Cash Burn

Initiation of Cubic Corporation (NYSE:CUB) with a Target Price of $17.80 (54% downside) by Glasshouse Research

Cubic Corporation’s suspect percentage-of-completion accounting infers that CUB has continued to miss milestones regarding their major projects. This is while management has obfuscated its financials by prematurely recognizing revenue in prior periods. Exacerbating our concerns, COVID-19 will massively amplify these milestone delays in major metropolitan cities with shutdowns.

Get The Full Series in PDF

Get the entire 10-part series on Charlie Munger in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues.

Q4 2019 hedge fund letters, conferences and more

  • Cubic Corp’s unbilled receivables have dwarfed its customer advances, surpassing historic levels at the firm. Surging contract assets and declining deferred revenues lead us to believe the company prematurely recognized approximately $108.5 million in TTM sales ($173.9 million in FY2019).
  • Contrary to sell-side analysts’ initial comments, the COVID-19 Virus and ensuing “shelter-in-place” laws will materially impact CUB’s major projects in New York, Boston, San Francisco, and Chicago. We believe this will exacerbate CUB’s already weak balance sheet and push milestone delays into massive losses for the firm.
  • Both reported and “adjusted” free-cash-flow figures provided by CUB management remain abysmal. If not for the company’s sale of its real estate assets ($44.9 million), factoring of its receivables ($31.1 million), and delaying of payments to suppliers ($50.2 million), we calculate that FCF has been cosmetically enhanced by $126.2 million in FY2019; for a true FCF value of –$162.2 million (vs management adjusted figure of +$14.1 million).
  • Cubic has needed to restate its financials in 8 of the last 13 fiscal years due to revenue recognition errors. Based on our analysis herein, we suggest that CUB’s earnings quality is in an even worse state now. As a result, GHR predicts Cubic may need to restate financials based on the magnitude of these ominous trends.

Cubic’s Dubious Past Gives GHR Cause for Concern

Management of Cubic Corporation (CUB) has been recently patting themselves on the back for a job well done reaching their Goal 2020 targets set back in late 2015. However, when our analysts looked under the hood, we found a management that has moved goalposts, changed the way they calculate performance metrics, and obfuscated their original targets to appease investors/analysts.

Since the time when the original Goal 2020 was announced, CUB replaced their Chief Financial Officer, divested their Defense Services segment, ramped up their acquisition activity, and changed performance target metrics from GAAP EPS to Adjusted EBITDA and Adjusted EPS. We believe all of this has played a major factor in reaching their “targets,” rather than from organic sources, as we will detail throughout the report.

Our investment thesis revolves around 1) management has prematurely recognized revenue on significant projects, 2) a large portion of awards have come from extremely low margin project wins and 3) the COVID-19 Virus and aftermath will hamper CUB’s business drastically over the next year and beyond. Moreover, where the Transportation Systems (CTS), Mission Solutions (CMS), and Defense System (CDS) segments have enjoyed substantial bookings/backlog gains in FY2018, these balances have cratered in FY2019 with no replenishment in sight. While the major projects in New York, Boston, San Francisco and Chicago have buoyed the stock price in 2018 and 2019, we opine that not only were these projects of low margin, but that management has been less than forthcoming with missed milestones and delays with these major projects.

After going through countless filings, earnings calls and presentations, we believe that Cubic management has been using a variety of accounting gimmicks to turn around a company that previously reported depressed margins and earnings. Based on our extensive experience researching accounting frauds, we take issue with both the quantity and scope of financial engineering used by management over the recent years.

When we analyze Cubic’s unsavory past, contract assets/liabilities diagnostics, and lackluster cash flow, we find a company that we believe has been manipulating its accounting for significant gains to the income statement. However, in our experience, the manipulation of all these balance sheet accounts points to share price degradation in upcoming periods as these issues tend to violently reverse.

Key Similarities Between Cubic Corporation and Tutor Perini

GlassHouse juxtaposes both Cubic Corporation and the past transgressions of similar construction company Tutor Perini (TPC) which we wrote on 03/17/16. We believe CUB has eerily similar PoC accounting red flags as TPC. The end result for Tutor Perini is not a pretty one. Litigations, claims, and unapproved change orders have decimated the company, but most importantly the stock price dropped over 80% as a result of management’s malfeasance.

Cubic

Cubic’s PoC Accounting Infers Missed Milestones and Delays

When analyzing past long-term contract companies such as Tutor Perini (TPC), a crucial harbinger in determining their future demise lies within its percentage-of-completion (PoC) accounting. When costs in excess of billings surge and inversely billings/deferred revenues decline relative to historical norms, we as analysts/accountants can predict: 1) future shortfalls in sales and earnings, 2) delays and missed milestones are encumbering certain projects, and/or 3) management may be recognizing revenue prematurely.

As such, we find that CUB’s receivables and deferred revenues1 trends all suggest that the company has been less than forthcoming regarding its future outlook. Furthermore, based on restatements made by Cubic due to these exact accounting errors in the past, we currently believe that the company is now in a much worse state than it was prior based on current accounting metrics. While there are new fresh faces at Cubic since its last announcement of restatements, we believe management is up to its same old financial engineering, as its poor earnings quality appears to have intensified.

Consider the software company Transaction Systems Architects, which became increasingly aggressive at picking up ever larger portions of its revenue at the front end and smaller portions at the back end. One sign that helped me discover this behavior was that new accounts began appearing on the balance sheet. The is not a good sign. Such accounts as unbilled receivables show up on the balance sheet… a telltale sign of accounting tricks. - Detecting Accounting Gimmicks that Destroy Investments, CFA Institute

Earnings quality and PoC accounting go hand-in-hand in determining future sales/earnings, as we can turn to balance sheet metrics as a future indication. Furthermore, when dealing with PoC accounting, there is a large emphasis on management subjectivity, estimates, and assumptions when compiling reported results. Focusing on these factors within Cubic’s most recent 10K, we highlight the following which pertains to our thesis:

Cubic

Based on our expertise within this sector, our analysts understand that these 10K excerpts are fairly boilerplate for companies with long-term contracts. However, eerily similar to Tutor Perini (TPC), we believe that Cubic is exhibiting significant adverse trends regarding its percentage-of-completion accounting. Due to the high influence of management (not outside auditors) in determining its own revenues and profits for each period, we believe there is high motivation for Cubic managers to game the system for their benefit, similar to what has happened in the past. Thus, we intend to show in our analysis why we believe the C-Suite at Cubic have been overly sanguine in recognizing recent revenues and profits; all at the expense of future earnings and potential restatements as in the past.

Unusual Growth in Contract Assets Pose a Significant Risk to Future Earnings

The adoption of ASC 606 by Cubic in Q1 2019 caused several changes to the company’s income statement and balance sheet, which we will detail throughout this report. With respects to the balance sheet and unbilled receivables, this account basically changed its moniker to “contract assets” from Q1 2019 onward. Therefore, we tracked these amounts over the past five years to find an inauspicious trend, which suggests missed milestones and delays that management has been less than forthcoming with. Again, we point out that this is not a collections issue, however, we believe this is a scope/overruns issue. Thus, our focus is mainly on unbilled receivables rather than billed. Because this is a revenue recognition concern, it bodes much worse for Cubic and its investors in the long run.

For our enthusiast readers, we do not have to emphasize how much our analysts loathe to see unbilled AR growing on the balance sheet of a company. If unbilleds/costs in excess of billings continue to grow and customer advances/billings in excess of costs continue to decline, this creates a cash flow problem, but it also means the following:

1) The company is spending faster than they are billing on their projects

2) The project managers are behind in getting their bills out, and/or

3) The company has costs on the balance sheet that are actually losses such as job overruns or change orders that are not or will not be approved.

In layman’s terms, unbilled AR represents revenue that has been recognized by management on the income statement which has not been invoiced or agreed upon by the client yet. Below, GHR lays out Cubic Corporation’s adverse contract assets trends, which we believe are a threat to CUB’s future persistence of earnings:

In the latest period (Q1 FY2020), 3M unbilled DSO2 rose by 10.4% YOY to a five-year high value of 93 days. Longer-term trends display 12M unbilled DSO rising by 10.3% YOY to 75 days, also representing a five-year high for the company (see Table 1, Page 8).

  • Unbilled receivables now account for over 73.8% of current receivables at the end of Q1 FY2020. This represents the third-highest value reported by Cubic in the last five-years (max 76.1% in Q3 FY2015).

Cubic

  • When we analyze CUB’s balance sheet, we see a multitude of moving parts with the firm’s unbilled receivables and long-term contract receivables, due to ASC 606 in 2019. Therefore, we need to be cognizant of the higher risk long-term AR accounts as well in our calculations. When including all of the balance sheet accounts of Contract Assets, Long-term Contract Receivables, Long-term Contracts Financing Receivables (including VIEs), and Long-term Capitalized Contract Costs (including VIEs), Cubic’s earnings quality related to its PoC accounting continues to worsen.
  • Accounting for the aforementioned line-items (which we will label “Total Contract Assets” or “Total CA”), we calculate that total contract assets increased by 14.4% YOY to $478.4 million in Q1 FY20203 (49.6% YOY to $501.4 million at Q4 FY2019).4
  • As a result, total contract assets increased by 851 bps YOY to 145.5%, relative to 3M sales at the end of Q1 FY2020. This value now stands 1,372 bps above the five-year seasonal average of 131.8% and reached a new five-year high in the quarter. Furthermore, total CA reached the third-highest value (31.5%) reported in any period relative to 12M sales in the past five years.

CUB

  • When monitoring CUB’s total CA using the days-sales-outstanding (DSO)5 calculation, the unfavorable trends are the same. Currently, total CA levels have risen double-digits to 136 days and 106 days of 3M and 12M total DSO, respectively (see Table 2, below).
  • Both these levels also stand at the firm’s five-year maximum. Sparking high concern, the last time Cubic reported a total CA DSO value over 100 was in 2014, when the company needed to restate its financials due to revenue recognition errors (as discussed later in our report).

 

Read the full article here by GlassHouse Research

The post Cubic burning through cash as insolvency risk looms ahead: Glasshouse Research appeared first on ValueWalk.

Read More

Continue Reading

Uncategorized

Analyst revamps MicroStrategy stock price target after Bitcoin buy

Here’s what could happen to MicroStrategy shares next.

Published

on

How does Michael Saylor feel about bitcoin? We'll let him tell you in his own words.

"Bitcoin is a swarm of cyberhornets serving the goddess of wisdom, feeding on the fire of truth, exponentially growing ever smarter, faster, and stronger behind a wall of encrypted energy," the executive chairman and co-founder of MicroStrategy  (MSTR)  once said.

Too subtle? Still not sure how the former CEO of the software intelligence company feels about the world's largest cryptocurrency? 

Maybe this will help.

"Bitcoin is a bank in cyberspace, run by incorruptible software, offering a global, affordable, simple and secure savings account to billions of people that don't have the option or desire to run their own hedge fund," Saylor said.

Okay, so the guy really likes bitcoin. And on March 19, the first day of spring, MicroStrategy took a bigger bite out of bitcoin when the company said it had bought 9,245 bitcoins for $623 million between March 11 and March 18.

MicroStrategy said it a completed a $603.75 million convertible debt offering — its second in a week — to raise money to buy bitcoin.

The company now holds about $13.5 billion of bitcoin, which adds up to more than 1% of the 21 million bitcoin that will ever exist, according to CoinDesk.

An analyst adjusts his price target for MicroStrategy

shutterstock

Committed to developing bitcoin network

MicroStrategy said in a regulatory filing that it had paid roughly $7.53 billion for its bitcoin stash, an average of $35,160 per coin.

The company's stock fell on Tuesday, while bitcoin posted its biggest single-day loss since November 2022. MicroStrategy was off slightly to $1,416 at last check on Wednesday and bitcoin was up 2.3% to $63.607.

Related: Analyst unveils Nvidia stock price 'line in the sand'

Phong Le, MicroStrategy’s president and CEO, told analysts during the company’s Feb. 6 fourth-quarter-earnings call that "we remain highly committed to our bitcoin strategy with a long-term focus.."

"We consider MicroStrategy to be the world's first bitcoin development company," he said. "We are a publicly traded operating company committed to the continued development of the bitcoin network through activities in the financial markets, advocacy, and technology innovation."

MicroStrategy earned $4.96 a share in the quarter, beating the FactSet consensus of a loss of 64 cents, and light years beyond the year-ago loss of $21.93 a share.

Revenue totaled $124.5 million, compared with FactSet's call for $133 million and the year-earlier tally of $132.6 million.

During the call, Saylor told analysts that "2024 is the year of birth of bitcoin as an institutional-grade asset class."

MicroStrategy, he said, completed the first 15 years of the bitcoin life cycle, back when it was largely unregulated and misunderstood. 

"The next 15 years, I would expect, will be a regulated, institutional, high-growth period of bitcoin, very, very different in many ways from the last 15 years," Saylor said.

Crypto's dark days

"Bitcoin itself is performing well for a number of reasons, but one reason is because it represents the digital transformation of capital," he added.

Of course, life with bitcoin wasn't always sunshine and roses. 

More Wall Street Analysts:

We take you back now to those less-than-thrilling days yesteryear, when covid-19 was on the rampage and the price of bitcoin fell 30% from March 8 to March 12 2020.

By the end of 2021, bitcoin had fallen nearly 30%. And 2023 saw the cryptocurrency sector wracked with bankruptcy and scandal, with the likes of FTX CEO Sam Bankman-Fried being convicted of fraud, conspiracy, and money laundering. 

SBF, as he has been known, is scheduled to be sentenced in Manhattan federal court on March 28. He faces a long stretch.

But bitcoin rose about 160% in 2023 and hit a record $73,750 on March 14.

Saylor recently said that his high hopes for bitcoin this year stemmed largely from the U.S. Securities and Exchange Commission approving spot bitcoin ETFs and the upcoming bitcoin halving, where when bitcoin's mining reward is split in half.

MicroStrategy is the first bitcoin development company, Saylor told analysts, but perhaps not for long. 

"We've published our playbook, and we're showing other companies how to do it," he said.

TD Cowen analyst Lance Vitanza cited MicroStrategy's latest bitcoin acquisition when he adjusted his price target for the company's shares on March 20.

The analyst cut the investment firm's price target on MicroStrategy to $1,450 from $1,560 and affirmed an outperform rating on the shares. 

He says the shares remain an attractive vehicle for investors looking to gain bitcoin exposure.

Related: Veteran fund manager picks favorite stocks for 2024

Read More

Continue Reading

Uncategorized

FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet

“This discovery unveils a potential novel molecular target for therapeutic strategies against hepatic steatosis during the aging process […]” Credit:…

Published

on

“This discovery unveils a potential novel molecular target for therapeutic strategies against hepatic steatosis during the aging process […]”

Credit: 2024 Kim et al.

“This discovery unveils a potential novel molecular target for therapeutic strategies against hepatic steatosis during the aging process […]”

BUFFALO, NY- March 20, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 5, entitled, “FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet.”

FoxO6, an identified factor, induces hyperlipidemia and hepatic steatosis during aging by activating hepatic lipoprotein secretion and lipogenesis leading to increased ApoC3 concentrations in the bloodstream. However, the intricate mechanisms underlying hepatic steatosis induced by elevated FoxO6 under hyperglycemic conditions remain intricate and require further elucidation.

In this new study, researchers Dae Hyun Kim, Seulah Lee, Sang Gyun Noh, Jaewon Lee, and Hae Young Chung from Pusan National University aimed to delineate the regulatory pathway involving ApoC3 controlled by FoxO6 and its resultant functional impacts.

“[…] we employed a spectrum of models including liver cell cultures, aged rats subjected to HFD, transgenic mice overexpressing FoxO6 (FoxO6-Tg), and FoxO6 knockout mice (FoxO6-KO).”

Their findings indicate that FoxO6 triggered ApoC3-driven lipid accumulation in the livers of aged rats on an HFD and in FoxO6-Tg, consequently leading to hepatic steatosis and hyperglycemia. Conversely, the absence of FoxO6 attenuated the expression of genes involved in lipogenesis, resulting in diminished hepatic lipid accumulation and mitigated hyperlipidemia in murine models. Additionally, the upregulation of FoxO6 due to elevated glucose levels led to increased ApoC3 expression, consequently instigating cellular triglyceride mediated lipid accumulation. The transcriptional activation of FoxO6 induced by both the HFD and high glucose levels resulted in hepatic steatosis by upregulating ApoC3 and genes associated with gluconeogenesis in aged rats and liver cell cultures.

“Our conclusions indicate that the upregulation of ApoC3 by FoxO6 promotes the development of hyperlipidemia, hyperglycemia, and hepatic steatosis in vivo, and in vitro. Taken together, our findings underscore the significance of FoxO6 in driving hyperlipidemia and hepatic steatosis specifically under hyperglycemic states by enhancing the expression of ApoC3 in aged rats.”
 

Read the full paper: DOI: https://doi.org/10.18632/aging.205610 

Corresponding Author: Hae Young Chung

Corresponding Email: hyjung@pusan.ac.kr 

Keywords: HFD-feeding, aging, forkhead transcription factor O6, ApoC3, lipid accumulation, hepatic steatosis

Click here to sign up for free Altmetric alerts about this article.

 

About Aging:

Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.

Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

Please visit our website at www.Aging-US.com​​ and connect with us:

  • Facebook
  • X, formerly Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Reddit
  • Pinterest
  • Spotify, and available wherever you listen to podcasts

 

Click here to subscribe to Aging publication updates.

For media inquiries, please contact media@impactjournals.com.

 

Aging (Aging-US) Journal Office

6666 E. Quaker Str., Suite 1B

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 1

###


Read More

Continue Reading

Uncategorized

ARPA-H appoints Etta Pisano to lead its Advancing Clinical Trials Readiness Initiative

The Advanced Research Projects Agency for Health (ARPA-H) has appointed Etta D. Pisano, MD, FACR, senior portfolio lead, to build the agency’s clinical…

Published

on

The Advanced Research Projects Agency for Health (ARPA-H) has appointed Etta D. Pisano, MD, FACR, senior portfolio lead, to build the agency’s clinical trial portfolio and lead the ARPA-H Advancing Clinical Trials Readiness Initiative under ARPA-H Resilient Systems Mission Office Director Jennifer Roberts.

Credit: N/A

The Advanced Research Projects Agency for Health (ARPA-H) has appointed Etta D. Pisano, MD, FACR, senior portfolio lead, to build the agency’s clinical trial portfolio and lead the ARPA-H Advancing Clinical Trials Readiness Initiative under ARPA-H Resilient Systems Mission Office Director Jennifer Roberts.

The first radiologist to be appointed to such a role, Dr. Pisano is an internationally recognized expert in women’s health, breast cancer research, and the use of artificial intelligence in medical imaging applications.

“I am honored to be working for ARPA-H to identify and promote research that can improve healthcare quality, efficacy and delivery, and to improve patient care and access to clinical trials for all Americans, including women, rural residents, and the underserved,” said Dr. Pisano.

Dr. Pisano will continue to serve as study chair of the large-scale Tomosynthesis Mammographic Imaging Screening Trial (TMIST) for the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). TMIST is led by ECOG-ACRIN with funding from the National Cancer Institute, part of the National Institutes of Health. She will also continue to serve as the American College of Radiology® (ACR®) Chief Research Officer (CRO). Dr. Pisano previously served as the principal investigator of the landmark Digital Mammographic Imaging Screening Trial (DMIST).

The TMIST breast cancer screening study is among the fastest growing National Cancer Institute (NCI) trials of the COVID-19 era. Under Dr. Pisano’s leadership, TMIST is assembling one of the most diverse cancer screening trial populations ever. Approximately 21% of TMIST U.S. participants are Black—more than double the average rate for Black participation in NCI-funded clinical trials (9%).

With ARPA-H, Dr. Pisano will work to build underserved and minority participation in clinical trials—including identifying and onboarding rural facilities and those outside of large academic medical centers—such as emerging retail healthcare sites. 

These duties are also very consistent with the missions of ECOG-ACRIN and ACR, which include promoting the exploration and identification of next-generation technologies that can benefit patients and providers.

“This is a great opportunity for Etta, and I’m excited about the impact she will make on our approach to clinical trials,” said Mitchell D. Schnall, MD, PhD, group co-chair of ECOG-ACRIN.

About ECOG-ACRIN

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is an expansive membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. The Group comprises nearly 1400 member institutions and 21,000 research professionals in the United States and around the world. ECOG-ACRIN is known for advancing precision medicine and biomarker research through its leadership of major national clinical trials integrating cutting-edge genomic approaches. Member researchers and advocates collaborate across more than 40 scientific committees to design studies spanning the cancer care spectrum, from early detection to management of advanced disease. ECOG-ACRIN is funded primarily by the National Cancer Institute, part of the National Institutes of Health. Visit ecog-acrin.org, and follow us on X @eaonc, Facebook, LinkedIn, and Instagram.

Media Contact: Diane Dragaud, Director of Communications, communications@ecog-acrin.org.


Read More

Continue Reading

Trending